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Background: To generate knowledge about potential improvements to human papillomavirus (HPV) vaccination
information and organization strategies, we assessed how aspects of HPV vaccination are associated with parents’
preferences for their daughters’ uptake, and which trade-offs parents are willing to make between these aspects.
Methods: A discrete choice experiment (DCE) was conducted among parents with a daughter aged 10–12 years.
Panel mixed logit regression models were used to determine parents’ preferences for vaccination. Trade-offs were
quantified between four vaccination programme aspects: degree of protection against cervical cancer, duration of
protection, risk of serious side-effects, and age of vaccination.
Results: Total response rate was 302/983 (31%). All aspects influenced respondents’ preferences for HPV vaccination
(p < 0.05). Respondents preferred vaccination at age 14 years instead of at a younger age. Respondents were willing
to trade-off 11% of the degree of protection to obtain life-time protection instead of 25 years. To obtain a
vaccination with a risk of serious side-effects of 1/750,000 instead of 1/150,000, respondents were willing to
trade-off 21%.
Conclusions: Uptake may rise if the age ranges for free HPV vaccinations are broadened. Based on the trade-offs
parents were willing to make, we conclude that uptake would increase if new evidence indicated outcomes are
better than are currently understood, particularly for degree and duration of protection.
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Human Papillomavirus (HPV) infection is a necessary fac-
tor in the development of cervical cancer [1]. Vaccines are
available against HPV 16 and 18, that are responsible for
71% of all cervical cancers worldwide [2]. Most European
countries offer the vaccine to girls aged between 9 to
17 years [3,4]. However, uptake rates vary considerably be-
tween countries (range 17-84%) [4]. In 2009, the Dutch
National Immunization Programme (NIP) was extended
to include the bivalent HPV vaccine for 12-year-old girls.
A catch-up campaign was organized in 2009 for 13 to
16 year old girls. The uptake rate of this campaign was* Correspondence: r.hofman@erasmusmc.nl
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unless otherwise stated.52% [5]. In 2010, 56% of all 12-year-old girls were vacci-
nated against HPV and in 2011 the uptake was 58% [6].
Vaccination through the NIP is voluntary, is free of
costs, and 12-year-olds are legally entitled to make their
own decision about uptake.
The attitude of parents and girls towards HPV vaccin-
ation and consequently its uptake, may be influenced by
their perception of the advantages and disadvantages of
the vaccine [7]. An advantage is the (partial) protection
against cervical cancer that the vaccine provides. The
fact that only partial protection is provided by HPV vac-
cinations may be considered a disadvantage: in spite of
HPV vaccinations, girls are still vulnerable to develop
cervical cancer [8]. Furthermore, insecurity about the
safety of the vaccine [8-11], anticipated side-effects such
as pain or discomfort [10,12], and cost [11,13,14] can bel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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come ambivalent towards HPV vaccination when they
weigh these ‘pros’ and ‘cons’ [8], and have, e.g., simul-
taneous positive and negative evaluations of an attitude
object [15,16], in this case HPV vaccination. This may
lead to postponing decisions about uptake, and hence,
low uptake rates, while a proportion of girls (and par-
ents) potentially had decided to have the HPV vaccin-
ation if better information had been available to them.
Our study aimed to generate knowledge to improve in-
formation and organization strategies. We therefore
wanted to assess which vaccine characteristics were
important for parents and girls when deciding about
uptake and which trade-offs they were willing to make
between these characteristics. We used a discrete choice
experiment (DCE), a quantitative approach that is in-
creasingly used in health care to elicit preferences [17,18].
Although Dutch girls are legally allowed to decide about
their own uptake, previous research showed that twelve to
thirteen year old girls made a shared decision with their
parents regarding uptake [19]. We therefore aimed at
assessing preferences for HPV vaccination in both girls
[20] and in parents. The current study describes the DCE
as conducted among parents.
Methods
Discrete choice experiment
In DCEs, it is assumed that a medical intervention,
such as a vaccination programme, can be described by
its characteristics (attributes; e.g. duration of protec-
tion) [21], and by variants of that characteristic (levels
of the attribute; e.g. a duration of protection of 6 years,
25 years and life-time). Furthermore, it is assumed that
individual preferences for a medical intervention are
determined by the levels of those attributes [21]. The
relative importance of attributes and the trade-offs that
respondents make between them can be assessed by of-
fering a series of choices between two or more medical
intervention alternatives with different combinations
of attribute levels (Table 1) [22]. A DCE is a straight-
forward task, which more closer resembles a real world
decision (i.e. trading off health and non-health out-
comes) in comparison with other stated preference
techniques [23]. We conducted the DCE according toTable 1 Choice set example
Attributes Program
Degree of protection against cervical cancer 70%
Duration of protection Lifetim
Risk of serious side-effects 1:750,
Age at vaccination 14 ye
Which vaccination programme do you prefer? • A
n.a. = not applicable.the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) DCE guideline [24] and
Lancsar and Louviere’s guide [25].
Attributes and attribute levels
The selection of attributes and their levels was based on
data from the literature [7]; focus groups with 36 parents
about decisional strategies and factors that could guide
HPV vaccination intentions [8]; and interviews with ex-
perts in the field of HPV vaccination, such as professors
in gynaecology, adolescent public health, and infectious
disease control (n = 8). This resulted in eight attributes
which were ranked by parents (n = 10) and the experts
(n = 8). The attributes identified as most relevant were:
1) the degree of protection against cervical cancer; 2) the
duration of protection; 3) the risk of serious side-effects
(e.g. hospitalization); and 4) the age of vaccination
(Table 2). These were included in the DCE design. Attri-
butes that were considered less relevant were total costs,
the risk of mild side-effects, the reduction in required
number of pap tests, and the HPV vaccine being recom-
mended by e.g. one’s general practioner/the government/
family or friends. Levels of the attributes were selected in
such a way that they were plausible and relevant from
both the clinical and the policy viewpoint. Levels of risk of
serious side-effects were based on a report of the Centers
for Disease Control and Prevention (CDC) (2009).
Study design
The combination of four attributes with three levels
each resulted in 81 (34) hypothetical HPV vaccination
alternatives. Using an efficient design by maximizing D-
efficiency (SAS software version 9.1, SAS Institute Inc.,
Cary, NC, USA), 54 choice sets were constructed to be
able to estimate all main effects and all two-way interac-
tions between attributes. Choice sets consisted of two
HPV vaccination alternatives and a ‘no HPV vaccin-
ation’ option to allow respondents to ‘opt out’ (Table 1).
HPV vaccination is a preventive medical intervention and,
as in real life, respondents are not obliged to opt for HPV
vaccination. Respondents were asked to consider all three
options in a choice set as realistic alternatives and to
choose the option that appealed most to them. Presenting
a single individual with a large amount of choice sets isme A Programme B No vaccination
90% 0%
e 6 years n.a.
000 1:750,000 No risk
ars 9 years n.a.
• B • None
Table 2 Considered attributes and levels for HPV
vaccination
Attributes Levels
Degree of protection against
cervical cancer (%)
50, 70, 90
Duration of protection (yrs) 6, 25, lifetime
Risk of serious side-effects (1 out of…) 750,000, 150,000, 30,000
Age at vaccination (yrs) 9, 12, 14
Hofman et al. BMC Public Health 2014, 14:454 Page 3 of 8
http://www.biomedcentral.com/1471-2458/14/454expected to result in a lower response rate and/or re-
sponse reliability [26,27]. We therefore used a blocked
design [22], which resulted in dividing the 54 choice
sets over six questionnaires containing nine choice sets
each.
Study sample
A sample of parents with a daughter aged 10–12 years
was approached through five primary school adminis-
trations in urban and rural areas in the Netherlands.
These school administrations consisted of a total of 57
schools, of which 55 were willing to participate. Calcu-
lation of optimal sample sizes for estimating non-linear
discrete choice models from DCE data is complicated as
it depends on the true values of the unknown parame-
ters estimated in the choice models [25]. One however
rarely requires more than 20 respondents per parameter
to estimate reliable models [25]. Our DCE contained 8
main-effect parameters (see equation 1). It, therefore,
needed to include at least 160 respondents.. Taking into
account some two-way interactions between attributes,
300 questionnaires was expected to be sufficient based
on other studies [24,28,29].
Questionnaire
The first page of the questionnaire provided information
about HPV and its link with cervical cancer, and HPV
vaccination. In the DCE section, respondents were asked
to choose the option that appealed to them most. A sepa-
rate sheet showed the percentages of the degree of protec-
tion illustrated with bar graphs, and a description of the
risk of serious side-effects in words (i.e. the risk of serious
side-effects is small, very small or extremely small).
We assessed respondents’ understanding of the DCE
task by including a dominant choice set as a rationality
test. In this choice set the HPV vaccine was given at the
age of 12 years in both alternatives, while one alternative
was characterized by logically preferable levels on all other
attributes. Convergent validity was checked with a ranking
task, i.e. ranking the four attributes of HPV vaccination
from most important to least important. To gain more
insight into respondents’ understanding of the DCE task,
i.e. comparing risks and percentages, we included the Sub-
jective Numeracy Scale (SNS), a scale that correlates wellwith objective measures of numeracy skills [30,31]. Higher
scores indicate higher numeracy.
The questionnaire was pilot tested to check for face
validity and for problems in interpretation (n = 16). This
resulted in an improved explanation of the risk of serious
side-effects. Approval for the study was obtained from
the Medical Ethics Committee, Erasmus MC, University
Medical Center Rotterdam (MEC 2008–206).
Questionnaires and information letters were sent to
primary schools between March and June 2009 to be
distributed to 10 to 12-year-old girls to give to their par-
ents. Parents could return the questionnaire in a postage-
paid envelope that was included in the mailing package.
Statistical analyses
The DCE was analysed by taking each choice among the
three options as an observation, i.e. two ‘no’ and one
‘yes’ responses. The observations were analysed by panel
mixed logit regression models to take heterogeneity as
well as correlation between the choice sets completed by
each individual into account [22]. After testing for linear
continuous effects of the attributes, we selected the
model with the best fit based on the Akaike information
criterion (AIC). Doing so, the following utility model
was estimated:
V ¼ β0 þ β1EFFECTIVENESSþ β2DURATION25Y
þβ3DURATIONLIFETIME
þβ4SERIOUS1=150; 000
þβ5SERIOUS1=30; 000þ β6AGE12Y
þβ7AGE14Y
ð1Þ
V is the observable utility that is composed of the
preference scores (β-coefficients) for the individual and
the characteristics of the HPV vaccination alternative.
β1-β7 are coefficients of the attributes indicating the
relative weight individuals place on a certain attribute
(level). When considering an HPV vaccination that gen-
erates a 50%, 70% or 90% protection rate, the coefficient
β1EFFECTIVENESS should be multiplied five, seven or
nine times, respectively. The statistical significance of a
coefficient (p-value ≤0.05) indicates that respondents
differentiated between one attribute (or attribute level)
and another in making stated choices about HPV vacci-
nation programmes. A priori, we expected all attributes to
be significant. The sign of a coefficient reflects whether
the attribute has a positive or negative effect on the prefer-
ence score of HPV vaccination. We expected that only the
attribute ‘risk of serious side-effects’ would have a negative
effect. The value of each coefficient represents the relative
importance respondents assign to an attribute (level).
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pact of excluding respondents who failed the rationality
test by excluding their data from the sample and re-
running the analysis [32,33]. Also a number of two-way
interactions between attributes were added to the main
effects model to test which ones were significant and
improved the fit of the model.
The trade-offs respondents were willing to make be-
tween the HPV vaccination attributes were calculated
by the ratios of the coefficients of the different attri-
butes with the degree of protection as the denomin-
ator. Choice probabilities for HPV vaccination uptake
were also calculated to provide a way to convey DCE
results to decision makers that is easier to interpret.
The probability that an individual will say “yes” to an
HPV vaccination programme is equal to:
P ¼ 1= 1þ e‐V  ð2Þ
where V is defined as in Equation 1. We calculated the
choice probability (i.e. the mean uptake) of a base-case
compared to no vaccination (V (no vaccination) = 0)). Our
base-case represents an HPV vaccination programme at
the age of 12 years, a 1/150,000 risk of serious side-effects,
a duration of protection of 6 years, and a 70% degree of
protection. This base-case was chosen to correspond with
i) the Dutch situation (vaccination at the age of 12 years)
and ii) an HPV vaccination programme that contained
most plausible levels based on literature. Noteworthy, in
the calculation of the mean uptake all heterogeneity of
the respondents was taken into account as the mean up-
take is not just equal to the uptake of someone with
average coefficient values of the levels. We presented
these results in a “tornado” graph to illustrate the mar-
ginal effect on uptake of varying one attribute level at aFigure 1 Univariate marginal estimates for change in predicted proba
attributes versus base-case. The base-case is an HPV vaccination at age 1
6 years, and 70% degree of protection against cervical cancer. This base-ca
our base-case, the expected uptake was 63.3%time from the base-case, holding all other attributes
constant [34] (Figure 1).Results
Respondents
The response rate was 302/983 (31%). In total, 294 out
of these 302 parents (97%) completed the DCE task and
were included for further analyses. The mean age of the
parents was 42.7 (SD = 3.4) years. 90% of the respon-
dents were female and about half had an intermediate
educational level (54%) and had a religious affiliation
(56%) (Table 3).DCE results
All vaccine characteristics proved to influence parents’
preferences for HPV vaccination (p < 0.05; Table 4). The
directions of the coefficients of the characteristics were
in accordance with our priori hypotheses, indicating the-
oretical validity. The positive directions of the coefficients
‘degree of protection’ and ‘duration of protection’ indi-
cated that parents preferred a higher protection rate and a
longer duration of protection over a lower protection rate
and a shorter duration of protection. The negative direc-
tion of serious side-effects indicated that parents preferred
an HPV vaccination programme with low levels of serious
side-effects. Most estimated standard deviations were sig-
nificant, which indicated preference heterogeneity among
respondents for several characteristics of HPV vaccination.
Parents did not prefer vaccination at age 12 years over
vaccination at the age of 9 years, but did prefer vacci-
nation at age 14 years over vaccination at age 9 years
(Table 4).
Sensitivity analyses showed that excluding the data of
five out of 294 parents (1.7%) who ‘failed’ the rationalitybility of participation of parents; highest and lowest value for
2 years, 1/150,000 risk of serious side-effects, duration of protection of
se is indicated as zero change in the probability of the x-axis. Assuming
Table 3 Respondent characteristics
(n = 294)
Characteristics
Age (years) Mean (SD) range 42.7 32-53 (3.4)
n (%)
Sex
Female 264 (90.1)
Educational level
Low 26 (9.3)
Intermediate 151 (53.9)
High 103 (36.3)
Religion
None 128 (43.7)
Christian 156 (53.2)
Muslim 1 (0.3)
Other 8 (2.7)
Country of birth
The Netherlands 272 (92.5)
Country of birth of parents
Both parents in the Netherlands 268 (96.8)
One parent outside the Netherlands 3 (1.1)
Both parents outside the Netherlands 6 (2.2)
Daughter HPV vaccinated
Yes 36 (12.4)
Intention if daughter not vaccinated
Yes 146 (58.4)
No 54 (21.5)
Don’t know 51 (20.3)
Job status
Paid job 259 (88.4)
Housewife or -man/unpaid job/student 28 (9.6)
No job 6 (2.0)
Marital status
Married/cohabiting 274 (93.8)
Partner, but living alone 7 (2.4)
No partner 11 (3.8)
Net income per month (euro’s)
< 1.500 13 (5.2)
1.500 – 3.000 113 (45.6)
3.000 – 4.500 86 (34.7)
> 4.500 36 (14.5)
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portance of the attributes. Adding two-way interactions
did not significantly improve the fit of the model (data
not shown).Ranking test and numeracy
The results of the ranking task showed that the most
important attributes were: the degree of protection (49%;
95% CI: 0.42 to 0.54); the risk of serious side-effects
(44%; 95% CI: 0.38 to 0.50); and the duration of protection
(5%; 95% CI: 0.03 to 0.09). These results are in accordance
with the DCE results (i.e. the order of importance is the
same as the order of the coefficients), supporting a conver-
gent validity of the DCE results.
Parents’ scores on the Subjective Numeracy Scale ranged
from 1.5 to 6.0 with a median of 4.6 (95% CI: 4.50 to
4.75, calculated with bootstrapping) and inter quartile
range (IQR) of 1.2 (data negatively skewed). The Cronbach
alpha coefficient was 0.88, suggesting very good internal
consistency reliability.
Trade-offs
Parents were willing to trade-off the degree of protection
against cervical cancer in order to gain improvement in
the levels of the other attributes. They were willing to
trade-off 11% of the degree of protection to obtain life-
time protection instead of 25 years. To obtain an HPV
vaccination with a risk of serious side-effects of 1/750,000
instead of 1/150,000, parents were willing to trade-off
21%. To get a vaccination at age 14 years instead of 9 years,
parents were willing to trade-off 10% (Table 5).
Expected uptake of HPV vaccination
Assuming our base-case HPV vaccination programme
(an HPV vaccination programme at the age of 12 years,
a 1/150,000 risk of serious side-effects; a duration of pro-
tection of 6 years, and a 70% degree of protection), the ex-
pected uptake based on parents’ preferences was 63.3%.
Especially an increase in the duration of protection from
6 years to lifetime would result in a relatively large in-
crease in the expected uptake (12.2%). On the other hand,
an increased risk of serious side-effects from 1/150,000 to
1/30,000 would result in a decrease in the expected uptake
(13.4%) (Figure 1).
Discussion
This study shows that the degree of protection against cer-
vical cancer, the duration of protection, the risk of serious
side-effects, and the age of vaccination, significantly influ-
enced parents’ preferences for HPV vaccination. Parents
preferred vaccination at age 14 years over age 9 years. Al-
though parents preferred a higher degree of protection
against cervical cancer, they were willing to trade-off some
degree of protection in order to gain improvement in the
levels of the other attributes.
Our finding that the duration and the degree of pro-
tection were relevant for parents’ preferences for HPV
vaccination was also found in a DCE study among
mothers [35]. Our study is innovative, in that we used
Table 4 Respondents’ preferences for HPV vaccination based on a panel mixed logit model [N = 294]
Attributes Coefficient
Value (95% CI)
Constant (vaccination) Mean −3.18 ***a (−4.50 to −1.86)
S.D. 9.26 *** (7.62 to 10.9)
Degree of protection against cervical cancer (per 10%) Mean 1.18b *** (0.99 to 1.36)
S.D. 0.75 *** (0.60 to 0.90)
Duration of protection 6 years (omitted)c Mean −2.37 *** (−2.72 to −2.03)
S.D. 1.46 *** (1.41 to 1.51)
Duration of protection 25 years Mean 0.56 *** (0.40 to 0.72)
S.D. 0.36 *** (0.10 to 0.62)
Duration of protection lifetime Mean 1.81 *** (1.51 to 2.11)
S.D. 1.42 *** (1.14 to 1.70)
1/750,000 risk of serious side effects (omitted)c Mean 3.04 *** (2.54 to 3.55)
S.D. 3.18 *** (2.98 to 3.38)
1/150,000 risk of serious side effects Mean 0.62 *** (0.37 to 0.86)
S.D. 0.70 *** (0.42 to 0.98)
1/30,000 risk of serious side effects Mean −3.66 *** (−3.06 to −4.25)
S.D. 3.11 *** (2.45 to 3.77)
Vaccination at age 9 years (omitted)c Mean −0.65 *** (−0.86 to −0.44)
S.D. 0.32 *** (0.30 to 0.33)
Vaccination at age 12 years Mean 0.11 (−0.06 to 0.29)
S.D. 0.29 *** (0.10 to 0.48)
Vaccination at age 14 years Mean 0.54 *** (0.36 to 0.72)
S.D. 0.29 *** (0.10 to 0.48)
Model fits
Log-Likelihood function −1205.62
Akaike information criterion 0.93
Bayesian information criterion 0.96
Pseudo R-squared 0.58
Notes: Effects coded variables used for protection duration, serious side effects, and age at vaccination; Normal distribution for random coefficients used on all
attributes; Number of observations = 7938 (i.e. 294 respondents completed 9 choice sets containing 3 response options each).
a***Denotes p < .01; bWhen looking at an HPV vaccination that generates a 50%, 70% or 90% protection rate, the coefficient should be multiplied five, seven or
nine times; cThe value of the omitted term equals the negative sum of the coefficients.
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vaccination), and that we sampled European parents.
Also, our findings were in line with the findings of a
DCE study, which investigated girls’ preferences for
HPV vaccination [20]. With the exception that parents
prefer vaccination at age 14 years instead of at a youn-
ger age, whereas girls prefer vaccination at age 12 years
over age 14 years [20]. Our findings are consistent withTable 5 Respondents’ trade-offs between degree of protectio
Change in levels Trade-of
A protection duration of lifetime instead of 25 years
A risk of serious side-effects of 1/750,000 instead of 1/150,000
A vaccination at age 14 years instead of 9 yearsthe results from the previous studies which found
that vaccine acceptability of parents increases as the
proposed age of vaccination increases (infant, preadoles-
cent and older teenagers) [10]. This might have im-
plications for vaccination programmes: uptake may
rise if the age ranges within which a girl is entitled
to free HPV vaccinations are broadened to e.g. 12 to
16 years.n and different aspects of a vaccination programme
f in a decreased degree of protection against cervical cancer (%; CI)
10.7 (8.6 to 12.7)
20.6 (15.9 to 25.3)
10.1 (8.3 to 11.9)
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programme was 63% based on parents’ preferences. This
rate is higher than the actual uptake of 52% in the
Netherlands in 2009 at the time our study was conducted
[5] and higher than the 58% of parents in our study who
intend to have their daughter vaccinated, but lower than
the uptake of other childhood vaccination in the Dutch
NIP, which is 95% [36]. A possible explanation might be
the current uncertainty considering several aspects of the
vaccine. Our results showed that the unknown duration
and degree of protection against cervical cancer and the
unknown risk of serious side-effects all played an impor-
tant role in parents’ choices about HPV vaccination up-
take. If for example the duration of protection was lifetime
instead of 6 years, the expected uptake would increase to
76-80%. To date, follow-up data on HPV vaccinated young
women are available for 8.4 years [37]. Therefore the ef-
fects of HPV vaccination on the long-term are unknown.
Furthermore, when the HPV vaccination campaign started
in the Netherlands in 2009, an intensive societal debate
involving politics, physicians, media, parents and girls
was ongoing. Contradictions in this debate could also
explain the low uptake. Possibly parents and girls be-
came ambivalent towards HPV vaccination, i.e. they
may have held simultaneous positive and negative feel-
ings towards HPV vaccinating, which can have a mode-
rating effect on attitude-intention and attitude-behavior
relationships resulting in postponing the decision about
uptake [38].
Our study has some limitations. First, the majority of
responding parents were mothers, although the question-
naire was addressed to both parents. This seems common
in studies assessing parental attitudes regarding HPV
vaccination [10,39,40]. We do not expect this limitation
to have biased the results. Second, the response rate of
parents was relatively low (31%). However, the rate is
similar to other DCE studies [28,41]. As indicated by
the high educational level of most parents, due to the
low response rate, our sample may not be representative
of the general population. This may limit the external
validity of our results. We recommend that in future
research ways are sought to include parents with a low
educational level in DCE studies. The relatively high
score for subjective numeracy score indicates that our
sample probably did understand the risks and percentages
they had to compare in the DCE task.
Conclusion
In conclusion, this study shows that parents’ preferences
for HPV vaccination were influenced by the degree of
protection against cervical cancer, the duration of pro-
tection, the risk of serious side-effects, and the age of
vaccination. Uptake may rise if the age ranges within
which a girl is entitled to free HPV vaccinations arebroadened. Based on the trade-offs parents were willing
to make, we conclude that uptake would increase if new
evidence indicated outcomes are better than are cur-
rently understood, particularly for degree and duration
of protection.
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